24WIL599 : Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination with Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer versus Historical Best Supportive Care

Principal Investigator

Ivy Wilkinson-Ryan

Study Number

STUDY02002599

Summary

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.

Phase

II

Contact

Kayla Fay

Available at the following location(s)

• Lebanon
• Manchester

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms